Clinical Experience with Trastuzumab (Herceptin)

Breast Journal

Volumn 9, Issue 6, 2003, Pages 452-462

  Vogel, Charles L ^a   Franco, Sandra X ^a  

^a Cancer Research Network   (United States)

Author keywords

Clinical trials; Herceptin; Targeted therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; PARACETAMOL; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST METASTASIS; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIPHORA; EPISTAXIS; EXPERIMENTAL MODEL; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG METASTASIS; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROTEIN BLOOD LEVEL; RESPIRATORY DISTRESS; REVIEW; RHINITIS; SINGLE DRUG DOSE; STEADY STATE; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0242721899     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09602.x     Document Type: Review

References (51)

1. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
2. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27(suppl 11):21-25.
3. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-89.
4. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
5. Gelmon K, Arnold A, Verma S, et al. Pharmacokinetics and safety of trastuzumab when administered every three weeks to women with metastatic breast cancer [abstract 271]. Proc Am Soc Clin Oncol 2001;20:69a.
6. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
7. Robertson JFR, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989;25:469-75.
8. Howell A, Mackintosh J, Jones M, et al. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
9. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol 1991;27:409-12.
10. Sledge GW, Loehrer PJ, Roth BJ, et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;6:1811-14.
11. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody again for metastatic breast cancer that overexpresses Her 2. N Engl J Med 2001;344:783-92.
12. Mass RD, Press M, Anderson S, et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract 85]. Proc Am Soc Clin Oncol 2001;20:22a.
13. Rahman ZU, Frye DK, Smith TL, et al. Results and long-term follow up for 1581 patients with metastatic breast cancer treated with standard-dose doxorubicin-containing chemotherapy. Cancer 1999;85:104-11.
14. Vogel CL, Nabhotz JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999;4:17-33.
15. Tripathy D, Slamon D, Leyland-Jones B, et al. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial [abstract 25]. Breast Cancer Res Treat 2000;64:32.
16. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
17. Mass R, Sanders C, Kasian C, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in Herceptin pivotal trials [abstract 291]. Proc Am Soc Clin Oncol 2000;19:75a.
18. Vogel CL, Cobleigh M, Tripathy D, et al. First-line, non-hormonal, treatment of women with Her 2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-Her 2 antibody) [abstract 275]. Proc Am Soc Clin Oncol 2000;19:71a.
19. Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37:25-29.
20. Vogel C, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol 2002;120:719-26.
21. Vogel CL, Cobleigh M, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization selected patients [abstract 86]. Proc Am Soc Clin Oncol 2001;20:22a.
22. Seidman AD, Fornier M, Esteva F, et al. Final report: weekly Herceptin and Taxol for metastatic breast cancer: analysis of efficacy by HER2 immunophenotype (immunohistochemistry) and gene amplification (fluorescent in situ hybridization) [abstract 319]. Proc Am Soc Clin Oncol 2000;19:83a.
23. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by Her 2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
24. Yeung K, Gupta R, Haidak D, et al. Weekly Herceptin and one hour Taxol infusion regimen for human epidermal growth factor receptor-2 overexpressed (+) metastatic breast cancer [abstract 559]. Proc Am Soc Clin Oncol 2000;19:142a.
25. Kuzur ME, Albain KS, Huntington MO, et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2 [abstract 512]. Proc Am Soc Clin Oncol 2000;19:131a.
26. Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-Her 2 monoclonal antibody plus docetaxel in patients with metastatic breast cancer: a pilot study [abstract 1987]. Proc Am Soc Clin Oncol 2001;20:60b.
27. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel and Herceptin as first or second line treatment in Her-2 overexpressing metastatic breast cancer [abstract 1949]. Proc Am Soc Clin Oncol 2001;20:50b.
28. Esteva FJ, Vacero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with Her 2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-808.
29. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
30. Jahanzeb M, Mortimer J, Yunus F, et al. Multicenter phase II trial of weekly Navelbine plus Herceptin in chemo-naive patients with Her2 positive metastatic breast cancer [abstract 1986]. Proc Am Soc Clin Oncol 2001;20:1986.
31. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for Her-2 overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895.
32. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Gemcitabine and trastuzumab for Her2 positive metastatic breast cancer: preliminary results of a phase II study [abstract 523]. Breast Cancer Res Treat 2001;69:302.
33. Bangemann N, Kuhle A, Ebert A, et al. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC) [abstract 653p]. Ann Oncol 2000;11:143.
34. Pienkowski T, Fumoleau P, Eiermann W, et al. Taxotere, cisplatin and Herceptin (TCH) in first-line Her2 positive metastatic breast cancer patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 001) [abstract 2030]. Proc Am Soc Clin Oncol 2001;20:70b.
35. Nabholtz JM, Riva A, Lindsay MA, et al. Docetaxel and trastuzumab in metastatic breast cancer: current data and future trials. Adv Breast Cancer 2002;4:2-5.
36. Hurley J, Doliny P, Silva O et al. Neoadjuvant Herceptin/Taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer [abstract 196]. Proc Am Soc Clin Oncol 2002;21:50a.
37. Yardley DA, Hainsworth JD, Greco FA, et al. Preserved chemosensitivity to weekly paclitaxel and carboplatin in Her 2+ patients irrespective of response to first line intensified Herceptin single agent therapy [abstract 127]. Proc Am Soc Clin Oncol 2002;21:33a.
38. Franco SX, Silva O, Bateman D, et al. Neoadjuvant treatment of locally advanced and inflammatory breast cancer with weekly Taxotere and carboplatin in tumors that do not overexpress Her2 [abstract 2048]. Proc Am Soc Clin Oncol 2002;21:59b.
39. Eidtmann H, Thomssen CH, Untch M, et al. Herceptin in combination with epirubicin plus cyclophosphamide: cardiac safety and efficacy in patients with metastatic breast cancer [abstract 236]. Proc Am Soc Clin Oncol 2002;21:60a.
40. Schueller J, Czejka M, Eder I, et al. Influence of Herceptin on pharmacokinetics and metabolism of epirubicin and docetaxel [abstract 464]. Proc Am Soc Clin Oncol 2001;20:117a.
41. Gianni L, Azbanell J, Eiermann W, et al. Feasibility pharmacology and anti-tumor activity of Herceptin with doxorubicin and Taxol followed by weekly Taxol in women with Her-2 positive advanced breast cancer [abstract 174]. Proc Am Soc Clin Oncol 2001;20:44a.
42. Theodoulou M, Campos S, Batist G, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advance breast cancer (ABC): final cardiac safety and efficacy analysis [abstract 216]. Proc Am Soc Clin Oncol 2002;21:55a.
43. Trigo J, Climent MA, Gil M, et al. Cardiac safety and activity of a phase I study of 3 weekly Myocet in combination with weekly Herceptin and paclitaxel in Her 2 positive locally advanced or metastatic breast cancer [abstract 242]. Proc Am Soc Clin Oncol 2002;21:61a.
44. Repka TL, Herwig K, Gay J, et al. A safe outpatient regimen of Herceptin and IL-2 in Her-2 positive metastatic breast cancer therapy [abstract 2008]. Proc Am Soc Clin Oncol 2001;20:65a.
45. Parihar R, Nadella P, Jensen R, et al. A phase I trial of Herceptin and interleukin-12 in patients with Her-2 overexpressing malignancies [abstract 1031]. Proc Am Soc Clin Oncol 2001;20:258a.
46. Parihar R, Nadella P, Jensen R, et al. Treatment of Her 2/neu overexpressing malignancies with Herceptin plus interleukin-12: correlation between increased interferon-gamma production and interferon-gamma gene polymorphism [abstract 51]. Proc Am Soc Clin Oncol 2002;21:14a.
47. Schwartz G, Rowinsky EK, Rha SY, et al. A phase I, pharmacokinetic and biologic correlative study of R11577 and trastuzumab in patients with advanced cancer [abstract 322]. Proc Am Soc Clin Oncol 2001;20:81a.
48. Osborne CK, Bardou VJ, Hilsenboek SG, et al. The estrogen receptor coactivator A1B1 (SRC 3) in combination with Her-2 is a prognostic and predictive marker in patients with breast cancer [abstract 129]. Proc Am Soc Clin Oncol 2002;21:33a.
49. Massarweh S, Show J, Monsin SK, et al. Inhibition of epidermal growth factor/Her2 receptor signaling using ZD1839 (Iressa) restores Tamoxifen sensitivity and delays resistance to estrogen deprivation in Her 2 overexpressing breast tumors [abstract 130]. Proc Am Soc Clin Oncol 2002;21:33a.
50. Harris KA, Washington CB, Lieberman G, et al. A population pharmacokinetics model for trastuzumab (Herceptin) and implications for clinical dosing [abstract 488]. Proc Am Soc Clin Oncol 2002;21-123a.
51. Carbonell Castellon X, Casteneda-Soto NJ, Clemens M, et al. Efficacy and safety of 3 weekly Herceptin monotherapy in women with Her2 positive metastatic breast cancer: preliminary report from a phase II study [abstract 73]. Proc Am Soc Clin Oncol 2002;21:19a.